NasdaqGS - Delayed Quote USD
XBiotech Inc. (XBIT)
At close: 4:00 PM EDT
After hours: 4:02 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
--
4,010.00
18,394.00
43,997.00
--
Cost of Revenue
1,681.00
--
651.00
5,820.00
34,548.00
--
Gross Profit
6,529.00
--
3,359.00
12,574.00
9,449.00
--
Operating Expense
42,925.00
37,510.00
37,849.00
37,656.00
27,725.00
--
Operating Income
-42,925.00
-37,510.00
-34,490.00
-25,082.00
-18,276.00
--
Net Non Operating Interest Income Expense
10,479.00
10,421.00
3,823.00
467.00
2,456.00
--
Other Income Expense
-2,352.00
2,776.00
-2,921.00
-843.00
2,993.00
--
Pretax Income
-34,798.00
-24,313.00
-33,588.00
-25,458.00
-12,827.00
--
Tax Provision
209.00
244.00
-688.00
-8,044.00
-1,606.00
--
Net Income Common Stockholders
-35,007.00
-24,557.00
-32,900.00
-17,414.00
-11,221.00
--
Diluted NI Available to Com Stockholders
-35,007.00
-24,557.00
-32,900.00
-17,414.00
-11,221.00
--
Basic EPS
-1.16
-0.81
-1.08
-0.58
-0.36
--
Diluted EPS
-1.16
-0.81
-1.08
-0.58
-0.36
--
Basic Average Shares
30,449.53
30,438.46
30,439.28
30,043.38
30,823.46
--
Diluted Average Shares
30,449.53
30,438.46
30,439.28
30,043.38
30,823.46
--
Total Operating Income as Reported
-42,925.00
-37,510.00
-34,490.00
-25,082.00
-18,276.00
--
Total Expenses
42,925.00
37,510.00
38,500.00
43,476.00
62,273.00
--
Net Income from Continuing & Discontinued Operation
-35,007.00
-24,557.00
-32,900.00
-17,414.00
-11,221.00
--
Normalized Income
-33,463.34
-26,052.47
-30,156.00
-16,927.68
-14,280.00
--
Interest Income
10,479.00
10,421.00
3,823.00
467.00
2,456.00
--
Net Interest Income
10,479.00
10,421.00
3,823.00
467.00
2,456.00
--
EBIT
-42,925.00
-37,510.00
-34,490.00
-25,082.00
-18,276.00
--
EBITDA
-41,192.00
-35,766.00
-31,876.00
-22,434.00
-16,038.00
--
Reconciled Cost of Revenue
1,681.00
--
651.00
5,820.00
34,548.00
--
Reconciled Depreciation
1,733.00
1,744.00
2,614.00
2,648.00
2,238.00
--
Net Income from Continuing Operation Net Minority Interest
-35,007.00
-24,557.00
-32,900.00
-17,414.00
-11,221.00
--
Total Unusual Items Excluding Goodwill
-1,954.00
1,893.00
-2,800.00
-711.00
3,496.00
--
Total Unusual Items
-1,954.00
1,893.00
-2,800.00
-711.00
3,496.00
--
Normalized EBITDA
-39,238.00
-37,659.00
-29,076.00
-21,723.00
-19,534.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-410.34
397.53
-56.00
-224.68
437.00
--
12/31/2019 - 4/15/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
XLS.SW Xlife Sciences AG
26.10
-4.74%
PRLD Prelude Therapeutics Incorporated
1.7800
-6.32%
ENTA Enanta Pharmaceuticals, Inc.
12.64
+0.08%
DSGN Design Therapeutics, Inc.
5.60
+0.09%
BION.SW BB Biotech AG Ord
37.75
+1.07%
XNCR Xencor, Inc.
21.08
-3.21%
ONCT Oncternal Therapeutics, Inc.
2.0900
+47.18%
INBX Inhibrx Biosciences, Inc.
15.50
-3.12%
PEPG PepGen Inc.
8.72
-2.46%
FNCH Finch Therapeutics Group, Inc.
12.14
+3.30%